Merck
CN
  • Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.

Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.

American journal of clinical pathology (2006-10-06)
Nirag Jhala, Darshana Jhala, Selwyn M Vickers, Isam Eltoum, Surinder K Batra, Upender Manne, Mohamad Eloubeidi, Jennifer J Jones, William E Grizzle
ABSTRACT

This study was undertaken to determine whether recently identified proteins could be translated to clinical practice as markers to distinguish pancreatic adenocarcinoma from chronic pancreatitis on fine-needle aspirate (FNA) samples. Resected pancreatic tissue sections (n = 40) and FNA samples (n = 65) were stained for clusterin-beta, MUC4, survivin, and mesothelin. For each biomarker, the staining patterns in adenocarcinoma and in reactive ductal epithelium were evaluated and compared. Clusterin-beta stained reactive ductal epithelium significantly more frequently than pancreatic adenocarcinoma (P < .001). In comparison, MUC4 and mesothelin were expressed more frequently in pancreatic adenocarcinoma on tissue sections. Positive staining for MUC4 (91% vs 0%; P < .001) and mesothelin (62% vs 0%; P = .01) and absence of staining for clusterin-beta (90% vs 7%; P < .001) were noted significantly more frequently in adenocarcinoma cells than in reactive cells in FNA samples. Clusterin-beta and MUC4 can help distinguish reactive ductal epithelial cells from the cells of pancreatic adenocarcinoma in FNA samples.